<DOC>
	<DOCNO>NCT01836185</DOCNO>
	<brief_summary>The purpose study measure much drug get bloodstream long take body remove give participant hepatic ( liver ) impairment compare participant normal hepatic function . Information side effect may occur also collect . This study last approximately 28 day , include screening .</brief_summary>
	<brief_title>A Study Evacetrapib ( LY2484595 ) Participants With Hepatic ( Liver ) Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Participants give write informed consent approve ethical review board ( ERB ) govern site Female participant nonchildbearing potential Have body mass index 18 40 kilogram per square meter ( kg/m^2 ) Healthy participant normal hepatic function determine medical history , physical examination , screen procedure Individuals hepatic impairment classify ChildPugh score A , B , C ( mild , moderate , severe impairment ) Has esophagus variceal bleed within 3 month checkin Have need take medication may interfere liver remove drug Have evidence cancer liver Consumes excessively large amount drink caffeine alcohol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>